Pushpa 2 Even though the Rule’s release is just ten days away, North American advance bookings have already exceeded $1.4 million.
Despite still being nine days out from its theatrical debut, Allu Arjun’s Pushpa 2: The Rule is already shattering box office records. The movie is scheduled for a global premiere, and if its pre-sales in the US are any guide, it should have a huge opening. In the US, the movie is already doing better than box office hits like Jawan and RRR.
read more: Vijay Deverakonda Breaks Silence on Rumours with Rashmika: ‘Love, Relationships, and Marriage’
Pushpa 2’s US tsunami
Venky Box Office, a trade tracker, released the movie’s advance booking totals for its US launch on Monday. The trade analyst posted on X (previously Twitter): “#Pushpa2TheRule USA Premiere Advance Sales: $1,383,949 – 900 Venues: 3420 Performances; 50008 Tickets Sold.
With ten days till its debut, Pushpa 2 has sold over 50,000 tickets in the US by Sunday night. The tweet went on to say that advance booking receipts in North America have surpassed $1.458 million, or about ₹12 crore, “which is a record.”
With nine days remaining, the movie is expected to surpass $1.5 million, surpassing the two largest Indian films in the US in recent memory, Jawan, starring Shah Rukh Khan, and RRR, directed by SS Rajamouli, according to trade analysts.
Both films are among the top five highest-grossing Indian films in North America, with each earning over $15 million. Pushpa 2 is behind just the all-time record holder for India in the US, Baahubali 2 (which made $20 million in the US), and is keeping up with Shah Rukh’s other 2023 smash, Pathaan.
Everything related to Pushpa 2: The Rise
The sequel to Sukumar’s 2021 pan-India smash Pushpa: The Rise is titled Pushpa 2: The Rise. Rashmika Mandanna, Fahadh Fassil, and Allu Arjun return as the anti-hero of the title. On December 5, the movie—hailed as one of the largest Indian productions ever—will be released.
Discover more from RVCJ News Media
Subscribe to get the latest posts sent to your email.